<DOC>
	<DOCNO>NCT02607332</DOCNO>
	<brief_summary>With discovery KIT mutation advent KIT tyrosine kinase inhibitor imatinib ( GlivecTM , Novartis ) , substantial improvement overall survival patient advance and/or metastatic gastrointestinal tumor ( GIST ) . Recently , sunitinib ( SuteneTM , Pfizer ) show activity second-line therapy GIST patient failure imatinib . However , virtually patient eventually progress become intolerable first-line imatinib second-line sunitinib .</brief_summary>
	<brief_title>A Trial Paclitaxel Patients With Metastatic Advanced Gastrointestinal Stromal Tumors ( GIST ) After Failure Imatinib Sunitinib</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Age 20 year old Histologically confirm metastatic and/or advance GIST CD117 ( cluster differentiation 117 ) ( + ) , DOG1 ( + ) , mutation KIT PDGFRα gene ( Platelet Derived Growth Factor Receptor ) Failed ( progressed and/or intolerable ) prior treatment GIST , include least imatinib sunitinib . Eastern Cooperative Oncology Group performance status 0~2 Resolution toxic effect prior treatment grade 0 1 NCICommon Toxicity Criteria Adverse Effects version 3.0 At least one measurable lesion define Response Evaluation Criteria In Solid Tumors version 1.0 Adequate bone marrow , hepatic , renal , organ function Neutrophil &gt; 1,500/mm3 Platelet &gt; 100,000/mm3 Hemoglobin &gt; 8.0 g/dL Total bilirubin &lt; 1.5 x upper limit normal ( ULN ) Aspartate aminotransferase /Alanine transferase &lt; 2.5 x ULN ( &lt; 5 x ULM case liver metastasis ) Creatinine &lt; 1.5 x ULN Life expectancy &gt; 12 week Washout period previous TKIs ( Tyrosine Kinase Inhibitor ) chemotherapy 4 time half life . Provision sign write informed consent Women childbearing potential pregnant breast feeding adult reproductive potential employ effective method birth control . presence cardiac disease , include myocardial infarction within 6 month prior study entry , Clinically significant cardiac disease ( New York Heart Association , Class III IV ) severe unstable angina pectoris , stroke transient ischemic attack , Arrhythmia need treatment Uncontrolled infection Diabetes mellitus ( insulin dependent independent disease , require chronic medication ) sign clinically significant peripheral vascular disease . Acute chronic liver disease chronic liver impairment . ( Patients stable chronic viral hepatitis eligible acceptable ) Uncontrolled gastrointestinal toxicity toxicity great NCI Common Toxicity Criteria Adverse Effects grade 2 Other severe , acute , chronic medical psychiatric condition laboratory abnormality . The patient experience bleed episode consider lifethreatening , grade 3 4 bleeding event . Major surgery ≤ 28 day prior start study drug recover side effect therapy . Known diagnosis HIV infection . History another primary malignancy currently clinically significant currently require active intervention . Patients brain metastasis assess radiologic image Alcohol substance abuse disorder .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>single-center</keyword>
	<keyword>prospective</keyword>
	<keyword>single-arm</keyword>
	<keyword>open-label</keyword>
	<keyword>phase II</keyword>
</DOC>